Literature DB >> 31032951

miRNA-143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro.

Leila Karimi1, Tahereh Zeinali1, Nayer Hosseinahli1, Behzad Mansoori1, Ali Mohammadi1, Mehdi Yousefi1, Milad Asadi1, Sanam Sadreddini1, Behzad Baradaran1, Dariush Shanehbandi1.   

Abstract

miR-143 is a tumor suppressor miRNA which its downregulation is frequently reported in colorectal cancer (CRC). This miRNA is a negative regulator of K-RAS, c-MYC, BCL-2, and MMP-9 genes which are engaged in tumor growth and metastasis. In the present study, miR-143 restoration was performed by transfection of the pCMV-miR-143 vector into the SW-480 CRC cells. Subsequently, alterations in proliferative and migratory potential of the cells were investigated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and wound-healing assays, respectively. Moreover, to detect apoptosis incidence in the transfected cells, 4',6-diamidino-2-phenylindole (DAPI) staining was used. Furthermore, mRNA levels of c-MYC, K-RAS, MMP-9, and BCL-2, as potential targets of miR-143, were assessed by quantitative Real-Time PCR (qRT-PCR). Also the expression levels of c-MYC, K-RAS, and MMP-9 proteins were investigated by the western blot analysis. Finally, the ratio of BAX to BCL-2 expression, as a potential marker of the response to apoptosis stimuli, was compared between the control and test groups. Furthermore, the trypan blue test was performed to determine the cell viability in cell suspension. According to the results, a decreased viability and migratory potential was observed for the miR-143 receiving cells. The DAPI staining also confirmed the occurrence of apoptosis. Moreover, BCL-2, K-RAS, MMP-9, and c-MYC mRNAs were significantly downregulated in the miR-143 grafted cells. The BAX/BCL-2 ratio also indicated a notable increase in the cells with miR-143 overexpression. In brief, miR-143 replacement could be considered as an effective strategy for the management of CRC and attenuating its invasive features.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  apoptosis; colorectal cancer; metastasis; miR-143 restoration; microRNA replacement therapy

Mesh:

Substances:

Year:  2019        PMID: 31032951     DOI: 10.1002/jcp.28745

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Deepak Narayanan Iyer; Lui Ng
Journal:  Histol Histopathol       Date:  2019-10-16       Impact factor: 2.303

2.  MiR-130a-3p suppresses colorectal cancer growth by targeting Wnt Family Member 1 (WNT1).

Authors:  Guang-Lin Song; Ming Xiao; Xiao-Ya Wan; Jun Deng; Jun-Da Ling; Ying-Guo Tian; Min Li; Jie Yin; Ren-Ying Zheng; Yi Tang; Gui-Yuan Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 3.  Approaches Toward Targeting Matrix Metalloproteases for Prognosis and Therapies in Gynecological Cancer: MicroRNAs as a Molecular Driver.

Authors:  Anuradha Pandit; Yasmin Begum; Priyanka Saha; Amit Kumar Srivastava; Snehasikta Swarnakar
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

4.  Restoration of miRNA-143 Expression Inhibits Growth and Migration of MKN-45 Gastric Cancer Cell Line.

Authors:  Nayer Hosseinahli; Tahereh Zeinali; Nasrin Hosseinahli; Leila Karimi; Dariush Shanehbandi; Behzad Mansoori; Ali Mohammadi; Tohid Kazemi; Khalil Hajiasgharzadeh; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2020-10-20

Review 5.  Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.

Authors:  Loretta László; Anita Kurilla; Tamás Takács; Gyöngyi Kudlik; Kitti Koprivanacz; László Buday; Virag Vas
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

6.  miR-203a-3p regulates the cellular processes of esophageal cancer cells via targeting CtBP2.

Authors:  Maorong Jiang; Hui Shi; Yunzhao Xu; Wen Bai; Peiwen Wang; Qianqian Ju
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.